Incyte (INCY) presented several analyses today from clinical studies of ruxolitinib, an oral...

|About: Incyte Corporation (INCY)|By:, SA News Editor

Incyte (INCY) presented several analyses today from clinical studies of ruxolitinib, an oral Janus kinase inhibitor that's FDA-approved for the treatment of patients with intermediate or high-risk myelofibrosis. Long-term results show that patients treated with the drug had improved survival rates over placebo and best available therapy. Additionally, data from ongoing trials suggest that long-term treatment may be an effective therapy for patients with polycythemia vera - a bone marrow disease that leads to an abnormal increase in the number of blood cells - as well.